(AIM) AIM ImmunoTech - Ratings and Ratios

AIM ImmunoTech Inc. (NYSE MKT: AIM) is a biotechnology company specializing in the development of immunotherapeutic drugs. The companys primary focus is on creating treatments for various cancers, viral infections, and immune system disorders. Its lead product, Ampligen, is a ribonucleic acid (RNA) molecule under investigation for chronic fatigue syndrome (CFS), pancreatic cancer, renal cell carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, and prostate cancer. Ampligen is also being studied for myalgic encephalomyelitis (ME), Hepatitis B, HIV, COVID-19, and post-COVID conditions. Additionally, the company offers Alferon N Injection, an alpha interferon treatment for human papillomavirus (HPV) and genital warts. AIM ImmunoTech has established collaborations with several research institutions and pharmaceutical companies, including Amarex Clinical Research, University of Cagliari, and Erasmus University Medical Center. Formerly known as Hemispherx Biopharma, the company rebranded as AIM ImmunoTech in August 2019. Founded in 1966, it is headquartered in Ocala, Florida.

Based on the provided and , the 3-month forecast for AIM ImmunoTech Inc. (NYSE MKT: AIM) suggests cautious optimism. The stocks average volume of 981,416 shares over 20 days indicates moderate liquidity. The last price of $0.13 is below the SMA 20 ($0.14) and SMA 50 ($0.18), signaling potential near-term weakness. However, the SMA 200 of $0.27 suggests that the stock may rebound if it can surpass the SMA 50 resistance level. The ATR of $0.02 reflects low volatility, which could stabilize price movements. On the fundamental side, the market cap of $9.14M and P/S ratio of 48.13 highlight the companys speculative nature and reliance on future growth prospects. With a P/B ratio of 3.17, the stock is trading above its book value, indicating investor confidence in its pipeline. Overall, the stock is likely to remain volatile, with potential upside if Ampligens clinical trials show positive results.